NCT00675090已完成1 期
A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.
研究概览
简要总结
This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimers disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated dose in the patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects with a clinical diagnosis of probable Alzheimer's disease
- •The subject has an MMSE score at screening of 12 to 26 for Part A and 16-26 for Part B.
- •Age ≥ 50 and above.
- •If female, the subject must be post-menopausal (i.e. 12 months without menstrual period) or surgically sterile.
- •Male subjects must be willing to abstain from sexual intercourse with pregnant or lactating women; or be willing to use a condom/spermicide in addition to having their female partner use another form of contraception if the woman could become pregnant, from the time of the first dose of GSK239512 until 84 days following completion of the study.
- •The subject has the ability to comply with the study procedures.
- •The subject has a permanent caregiver and is willing to attend all study visits for Parts A and B.
- •The subject has provided full written informed consent prior to the performance of any protocol specific procedure, or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative.
- •The caregiver has provided his / her written consent prior to the performance of any protocol specific procedure.
排除标准
- •In the opinion of the investigator, following review of CT/MRI scans in the past 12 months and completion of neurological review there could be other probable causes of dementia
- •History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study, or current depression (a score of ≥8 on the Cornell Scale for Depression in Dementia), or subjects with other psychiatric features in their AD which would in the opinion of the investigator, would increase risk to safety.
- •History of significant sleep disturbance, for example, when it is associated with nocturnal wandering, nocturnal confusion / disorientation / agitation, which in the opinion of the investigator, may increase safety risk.
- •History or presence of known or suspected seizures, unexplained significant loss of consciousness within last 6 months. Subjects who had febrile seizures in childhood may be included if these ceased by age 10 and they have had no other type of seizure in their medical history and have not been on anti-epileptic medications.
- •History or presence of significant cardiovascular, gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.
- •History of alcohol or other substance abuse, according to the Diagnostic and Statistical Manual of Mental Disorders - Substance related disorders (DSM-IV) criteria.
- •Clinically significant abnormalities in laboratory tests, including subjects with active liver disease or uncontrolled thyroid disease.
- •Uncontrolled hypertension with systolic BP ≥160 and/or diastolic ≥95 mmHg. Subjects with controlled hypertension with systolic BP < 160 mmHg and diastolic <95 mmHg for at least 4 weeks are acceptable.
- •Systolic BP <100 mmHg and/or diastolic <60 mmHg.
- •Subjects with ECG criteria outside ranges specified in the protocol
- •History of hypersensitivity to GSK239512 or its excipients.
- •Treatment with cholinesterase inhibitors, (including Tacrine), memantine or selegiline within the previous month. No patients with AD who are already on these medications at the time of screening will be recruited, as it would be unethical to withdraw these medications for study participation. Only AD subjects who are not yet on these medications, or who have withdrawn from these medications for other reasons previously, may be enrolled into this study.
- •Subjects who are currently taking or who have taken in the last month anti-psychotic drugs (typical or atypical dopaminergic antagonists or modulators) or mood stabilization drugs (including SSRI, DNRI, SNRI, MAO inhibitors, tricyclic antidepressants, lithium, valproate, carbamazepine).
- •Subjects who are currently taking Pgp inhibitors or any CYP3A4 inhibitors.
- •Subjects on chronic sedative medications (≥ 4 days per week for the past 4 weeks).
- •Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.
- •Has received any other investigational treatment in the previous 3 months.
研究组 & 干预措施
GSK239512
Experimental
GSK239512 oral tablets
干预措施: GSK239512 (Drug)
Placebo
Placebo Comparator
Placebo to match tablets
干预措施: Placebo (Drug)
结局指标
主要结局
Safety and tolerability as measured by adverse events, vital signs clinical laboratory measurements and validated clinical assessment scales.
时间窗: Days 8, 15, 22 and 29
次要结局
- Pharmacodynamics measured by computerized cognitive tests and validated clinical rating scales. Also investigating the Pharmacokineticsat trough concentrations (Cmin) after GSK239512 repeat dosing on days 8, 15, 22 and 29 and 15.(days 8, 15, 22 and 29)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary CholangitisCholestasisNCT02966834GlaxoSmithKline147
已完成
1 期
A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal SubjectsDiabetes Mellitus, Type 2NCT00823940GlaxoSmithKline42
已完成
1 期
Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy SubjectsMalariaNCT00675064GlaxoSmithKline41
已完成
1 期
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy VolunteersType 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00501930GlaxoSmithKline12
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese SmokersPulmonary Disease, Chronic ObstructiveNCT01762774GlaxoSmithKline56